Table 2 Changes in tumor volume and SUVmax in ICON patients with abnormal nodes post-therapy.

From: Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

ICON cohort

     
  

Pre-chemotherapy

Post-chemotherapy

Change (Post–Pre)

 
 

n

Median (min, max)

Median (min, max)

Median (min, max)

P value

Tumor volume (mL)

8*

68.2 (2.50, 207)

20.6 (2.60, 94.0)

−35.9 (−113, 0.10)

0.016

Tumor SUVmax

3**

9.30 (7.10, 19.0)

8.90 (6.50, 9.60)

0.30 (−14.4, 1.80)

1.00

  1. ICON ImmunogenomiC prOfiling in Non-small cell lung cancer. *Post-chemotherapy tumor volume was not measurable (atelectasis) in one patient. **Six patients did not have paired tumor SUVmax values. SUVmax, maximum standardized uptake value. Two-sided P value is from Wilcoxon signed-rank test for paired tumor volume and tumor SUVmax comparisons. Source data are provided as a Source Data file.
Back to article page